OTCPK:BMXM.F

Stock Analysis Report

Executive Summary

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases.

Snowflake

Fundamentals

Flawless balance sheet with questionable track record.


Similar Companies

Share Price & News

How has bioMérieux's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.7%

BMXM.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

-10.7%

BMXM.F

9.5%

US Medical Equipment

1.1%

US Market

BMXM.F underperformed the Medical Equipment industry which returned 9.9% over the past year.

BMXM.F underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

BMXM.FIndustryMarket
7 Day3.7%0.7%-0.2%
30 Day-3.4%0.1%2.5%
90 Day-8.2%2.5%1.6%
1 Year-10.7%-10.7%10.4%9.5%3.4%1.1%
3 Year-49.0%-49.0%69.3%64.1%45.2%35.8%
5 Year-25.2%-25.2%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is bioMérieux's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is bioMérieux undervalued based on future cash flows and its price relative to the stock market?

33.05x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

bioMérieux's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

bioMérieux's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

bioMérieux is good value based on earnings compared to the US Medical Equipment industry average.

bioMérieux is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

bioMérieux is poor value based on expected growth next year.


Price Based on Value of Assets

bioMérieux is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is bioMérieux expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

11.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

bioMérieux's revenue is expected to grow by 7.1% yearly, however this is not considered high growth (20% yearly).

bioMérieux's earnings are expected to grow by 11.7% yearly, however this is not considered high growth (20% yearly).

bioMérieux's revenue growth is positive but not above the United States of America market average.

bioMérieux's earnings growth is positive but not above the United States of America market average.

bioMérieux's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

bioMérieux is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has bioMérieux performed over the past 5 years?

18.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

bioMérieux's year on year earnings growth rate has been positive over the past 5 years.

bioMérieux's 1-year earnings growth is negative, it can't be compared to the 5-year average.

bioMérieux's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

bioMérieux has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

bioMérieux used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

bioMérieux's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is bioMérieux's financial position?


Financial Position Analysis

bioMérieux is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

bioMérieux's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

bioMérieux's level of debt (25.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (31.4% vs 25.4% today).

Debt is well covered by operating cash flow (77.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 23.5x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.5x debt.


Next Steps

Dividend

What is bioMérieux's current dividend yield, its reliability and sustainability?

0.67%

Expected Dividend Yield


Dividend Yield and Payments Analysis

bioMérieux's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

bioMérieux's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

bioMérieux is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

bioMérieux is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of bioMérieux's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of bioMérieux's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of bioMérieux's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Alexandre Mérieux (45yo)

1.8yrs

Tenure

€2,595,330

Compensation

Mr. Alexandre Mérieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Mérieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined ...


CEO Compensation Analysis

Alexandre's remuneration is lower than average for companies of similar size in United States of America.

Alexandre's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.


Management Age and Tenure

1.5yrs

Average Tenure

45yo

Average Age

The average tenure for the bioMérieux management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.8yrs

Average Tenure

61.5yo

Average Age

The tenure for the bioMérieux board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Guillaume Bouhours (43yo)

    Executive VP of Finance

    • Tenure: 1.5yrs
  • Alexandre Mérieux (45yo)

    Chairman & CEO

    • Tenure: 1.8yrs
    • Compensation: €2.60m
  • Michel Baguenault

    Executive VP & Company Secretary

    • Tenure: 0.7yrs
  • François Lacoste

    Executive Vice President of Clinical Unit

    • Tenure: 1.5yrs
  • Stefan Willemsen

    Executive Vice President of Americas Region

    • Tenure: 1.5yrs
  • Mark Miller

    Executive VP & Chief Medical Officer

    • Tenure: 6.9yrs
  • Nicolas Cartier (52yo)

    Executive Vice President of Industrial microbiology Unit

    • Tenure: 1.5yrs
  • Pierre Charbonnier

    Executive Vice President of Global Quality

    • Tenure: 1.5yrs
  • Sylvain Morgeau

    Investor Relations

    • Tenure: 0yrs
  • Valérie Leyldé

    Executive VP of Human Resources and Communications

    • Tenure: 0.7yrs

Board Members

  • Alain Merieux (81yo)

    Founding Chairman

    • Tenure: 2.1yrs
  • Jean-Luc Bélingard (71yo)

    Non-Independent Director

    • Tenure: 13yrs
    • Compensation: €41.00k
  • Philippe Archinard (60yo)

    Non-Independent Director

    • Tenure: 9.3yrs
    • Compensation: €55.00k
  • Alexandre Mérieux (45yo)

    Chairman & CEO

    • Tenure: 1.8yrs
    • Compensation: €2.60m
  • Harold Y. Boël (55yo)

    Independent Director

    • Tenure: 7.3yrs
    • Compensation: €55.00k
  • Agnès Lemarchand (65yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: €46.00k
  • Marie-Hélène Habert-Dassault (54yo)

    Independent Director

    • Tenure: 7.3yrs
    • Compensation: €36.00k
  • Fanny Letier (40yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: €36.00k
  • Marie-Paule Kieny (64yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: €30.00k
  • Frédéric Besème (63yo)

    Employee director

    • Tenure: 1.3yrs
    • Compensation: €13.12k

Company Information

bioMérieux S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: bioMérieux S.A.
  • Ticker: BMXM.F
  • Exchange: OTCPK
  • Founded: 1963
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €8.704b
  • Listing Market Cap: €9.619b
  • Shares outstanding: 118.10m
  • Website: https://www.biomerieux.com

Number of Employees


Location

  • bioMérieux S.A.
  • 376 Chemin De l’Orme
  • Marcy l'Etoile
  • Rhône-Alpes
  • 69280
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMXM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2004
BIMENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2004
0RUGLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2004
EYWNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2004
BIMPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2004

Biography

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:31
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.